HARD Syndrome

HARD Syndrome: A Comprehensive Medical Review

Introduction

HARD syndrome, which stands for Hydrocephalus, Agyria, Retinal Dysplasia (with or without Encephalocele, making it HARD±E syndrome), is the original terminology for what is now more commonly known as Walker-Warburg syndrome (WWS). According to trusted medical organizations including the National Institutes of Health (NIH), Orphanet, and the National Organization for Rare Disorders (NORD), this condition represents the most severe form of congenital muscular dystrophy associated with brain and eye abnormalities. The syndrome was first described by Mette Warburg in 1971 and later characterized more comprehensively by Arthur Earl Walker, leading to its current designation as Walker-Warburg syndrome, though the HARD syndrome nomenclature remains in use in medical literature.^{[1][2][3][4][5]}

Definition and Classification

Disease Definition

According to Orphanet, Walker-Warburg syndrome (HARD syndrome) is defined as “a rare form of congenital muscular dystrophy (CMD) associated with severe brain and eye abnormalities. It is the most severe form of CMD”. The condition is classified under multiple medical taxonomies:^[5]

• OMIM Classification: #236670 (Walker-Warburg syndrome)
• Orphanet Code: ORPHA:899
• ICD-10: Q04.3

Synonyms and Nomenclature

The condition is known by several names in medical literature:^[2][6][1]

• HARD syndrome (Hydrocephalus, Agyria, Retinal Dysplasia)
• HARD±E syndrome (with or without Encephalocele)
• Walker-Warburg syndrome (WWS)
• Warburg syndrome
• Chemke syndrome
• Pagon syndrome
• Cerebroocular dysplasia-muscular dystrophy syndrome (COD-MD)
• Cerebroocular dysgenesis (COD)

Epidemiology and Demographics

Prevalence and Geographic Distribution

HARD syndrome/Walker-Warburg syndrome is an extremely rare condition with limited epidemiological data:

Global Prevalence: According to Orphanet, the prevalence is estimated at 1-9 per 1,000,000 individuals worldwide.^[5]

Incidence: The incidence is estimated at 1-2 per 100,000 live births globally.^[7][5]

Geographic Distribution: The syndrome has a worldwide distribution with no specific ethnic or geographic clustering, though a survey in Northeastern Italy reported an incidence rate of 1.2 per 100,000 live births.^[7]

Demographic Characteristics

Age at Presentation: The condition is typically apparent at birth or in early infancy due to the severity of manifestations.^[7][5]

Gender Distribution: The condition affects both males and females equally, consistent with its autosomal recessive inheritance pattern.^[5][7]

Family History: Given the autosomal recessive inheritance, affected individuals typically have unaffected parents who are carriers, though consanguinity increases the risk.^[7]

Pathophysiology and Molecular Mechanisms

Genetic Basis

HARD syndrome/Walker-Warburg syndrome is caused by mutations in multiple genes involved in the glycosylation of α-dystroglycan, collectively known as dystroglycanopathies:^[8][9][10]

Primary Genes Involved:^[11][8][7]

• POMT1 (Protein O-mannosyltransferase 1): Located on chromosome 9q34
• POMT2 (Protein O-mannosyltransferase 2): Located on chromosome 14q24
• POMGNT1 (Protein O-mannose beta-1,2-N-acetylglucosaminyltransferase): Associated with muscle-eye-brain disease
• FKTN (Fukutin): Associated with Fukuyama congenital muscular dystrophy
• FKRP (Fukutin-related protein): Involved in limb-girdle muscular dystrophy
• LARGE (Like-acetylglucosaminyltransferase): Involved in congenital muscular dystrophy

Molecular Pathophysiology

α-Dystroglycan Hypoglycosylation:^[9][12][7]
The central pathophysiological mechanism involves defective glycosylation of α-dystroglycan, a crucial protein in the dystrophin-glycoprotein complex. This complex serves multiple functions:

• Muscle stabilization: Links the cytoskeleton to the extracellular matrix in muscle fibers
• Neuronal migration: Guides proper neuronal migration during brain development
• Cell adhesion: Maintains cellular integrity in various tissues

POMT Complex Function:^[9][11]
The POMT1 and POMT2 proteins form a heterodimeric enzyme complex that catalyzes the first step in O-mannosylation of α-dystroglycan by transferring mannose from dolichyl phosphate mannose to serine or threonine residues on the protein.

Pathogenic Consequences:^[9][7]
When POMT enzyme complexes are nonfunctional due to mutations:

• α-dystroglycan cannot be properly glycosylated
• The protein loses its ability to anchor cells to the extracellular matrix
• Muscle fibers become unstable and undergo degeneration
• Neuronal migration is disrupted, leading to brain malformations
• Eye development is affected, causing various ocular abnormalities

Clinical Manifestations

The HARD Acronym Components

The syndrome’s name reflects its four cardinal features, each representing severe developmental abnormalities:^[3][13][1]

H – Hydrocephalus

Cerebrospinal Fluid Accumulation:^[14][5][7]

• Prevalence: Present in virtually all cases as a constant feature
• Severity: Often severe and progressive, leading to macrocephaly
• Mechanism: Due to brain malformations affecting CSF circulation
• Complications: May require ventriculoperitoneal shunting
• Prenatal detection: Often visible on fetal ultrasound

A – Agyria (Lissencephaly Type II)

Brain Surface Abnormalities:^[4][5][7]

• Cobblestone lissencephaly: Brain surface lacks normal folds and appears bumpy and irregular
• Neuronal migration defect: Neurons migrate past their intended destinations
• Cortical disorganization: Abnormal laminar structure of the cerebral cortex
• Associated features: May include absence of corpus callosum
• Functional impact: Severe intellectual disability and developmental delays

R – Retinal Dysplasia

Eye Abnormalities:^[4][5][7]

• Retinal detachment: Congenital nonattachment of the retina
• Retinal dysplasia: Abnormal retinal development and structure
• Other ocular features: May include microphthalmia, cataracts, glaucoma
• Visual impact: Severe visual impairment or blindness
• Anterior chamber defects: Shallow anterior chamber, corneal opacities

D – Additional Features (±E for Encephalocele)

Encephalocele:^[13][5][7]

• Prevalence: Present in approximately 50% of cases
• Location: Usually occipital region
• Mechanism: Failure of neural tube closure during development
• Associated features: May be accompanied by Dandy-Walker malformation

Associated Clinical Features

Muscular Manifestations

Congenital Muscular Dystrophy:^[4][5][7]

• Severe hypotonia: “Floppy baby” syndrome from birth
• Progressive muscle weakness: Affecting all voluntary muscles
• Elevated creatine kinase: Significantly increased serum levels
• Muscle atrophy: Progressive wasting of muscle tissue
• Contractures: Development of fixed joint deformities

Neurological Features

Developmental and Cognitive:^[14][5][7]

• Severe intellectual disability: Profound developmental delays
• Seizures: Present in some patients, various types possible
• Hyporeflexia: Diminished or absent deep tendon reflexes
• Poor feeding: Difficulty with sucking and swallowing
• Respiratory problems: Due to muscle weakness affecting breathing

Additional Systemic Features

Other Abnormalities:^[15][5][7]

• Facial dysmorphism: May include micrognathia, cleft lip/palate
• Genitourinary abnormalities: Small penis, undescended testes
• Cardiac defects: Occasionally present
• Growth retardation: Poor weight gain and linear growth

Diagnostic Approach

Clinical Diagnosis

The diagnosis of HARD syndrome/Walker-Warburg syndrome is primarily clinical, based on the recognition of the characteristic constellation of features:^[14][7]

Diagnostic Criteria:^[5][7]

1. Congenital muscular dystrophy with hypoglycosylation of α-dystroglycan
2. Elevated creatine kinase levels in serum
3. Anterior or posterior eye anomalies
4. Brain migration defect with type II lissencephaly

Laboratory Investigations

Biochemical Assessment

Muscle-Related Tests:^[14][7]

• Creatine kinase (CK): Markedly elevated (often >3000 IU/L)
• Muscle biopsy: Shows dystrophic changes with increased connective tissue
• Immunohistochemistry: Demonstrates reduced or absent α-dystroglycan staining
• Electron microscopy: Reveals disrupted sarcomere structure

Genetic Testing

Molecular Diagnosis:^[12][10][8]

• Gene panel testing: Comprehensive testing of all known dystroglycanopathy genes
• POMT1 sequencing: Most commonly mutated gene in Walker-Warburg syndrome
• POMT2 analysis: Second most common genetic cause
• Functional studies: Assessment of enzyme activity when indicated

Imaging Studies

Neuroimaging

Magnetic Resonance Imaging (MRI):^[7][14][5]

• Cobblestone lissencephaly: Characteristic bumpy brain surface
• Hydrocephalus: Enlarged ventricles
• Cerebellar abnormalities: Hypoplasia of cerebellum and brainstem
• White matter changes: Hypomyelination and structural abnormalities
• Corpus callosum: May be absent or hypoplastic

Prenatal Imaging:^[16][15]

• Fetal ultrasound: Can detect hydrocephalus, encephalocele
• Fetal MRI: Better characterization of brain abnormalities
• Early detection: Possible from second trimester onwards

Ophthalmological Assessment

Comprehensive Eye Examination:^[14][7]

• Fundoscopy: Reveals retinal detachment and dysplasia
• Anterior segment evaluation: Assessment for cataracts, glaucoma
• Visual function testing: Usually severely impaired
• Specialized imaging: OCT and other advanced techniques when feasible

Prenatal Diagnosis

Antenatal Detection:^[16][7]

• Ultrasound screening: Detection of hydrocephalus and encephalocele
• Fetal MRI: Advanced brain imaging for detailed assessment
• Genetic testing: Available for families with known mutations
• Counseling: Comprehensive genetic counseling essential

Differential Diagnosis

Primary Considerations

Muscle-Eye-Brain Disease (MEB)

Similarities and Differences:^[17][18][19]

• Similarities: Muscular dystrophy, brain abnormalities, eye defects
• Key differences:
  • Survival: MEB patients typically survive into childhood/adolescence
  • Severity: Less severe overall phenotype than Walker-Warburg
  • Geographic distribution: More common in Finland
  • Genetic basis: Primarily POMGNT1 mutations

Fukuyama Congenital Muscular Dystrophy (FCMD)

Distinguishing Features:^[20][17]

• Eye involvement: Less prominent or absent ocular abnormalities
• Geographic distribution: Primarily in Japanese populations
• Brain abnormalities: Cobblestone lissencephaly less severe
• Genetic basis: FKTN gene mutations

Secondary Considerations

Other Congenital Muscular Dystrophies:

• LAMA2-related CMD: Merosin deficiency, normal brain structure
• COL6-related CMD: Bethlem myopathy and Ullrich CMD
• SELENON-related CMD: Rigid spine syndrome

Isolated Hydrocephalus:

• Non-syndromic hydrocephalus: No associated muscle or eye abnormalities
• Other causes: Aqueductal stenosis, Dandy-Walker malformation

Treatment and Management

Current Treatment Approaches

Supportive and Symptomatic Care: No specific curative treatment exists; management focuses on supportive care and prevention of complications:^[5][7]

Neurological Management

Hydrocephalus Treatment:^[14][5]

• Ventriculoperitoneal shunting: Primary treatment for progressive hydrocephalus
• Monitoring: Regular assessment for shunt malfunction
• Complications: Risk of infection, blockage, over-drainage
• Revision surgery: Often required due to growth and complications

Seizure Management:^[5]

• Anticonvulsant therapy: When seizures are present
• EEG monitoring: Regular assessment of seizure activity
• Medication selection: Consideration of drug interactions and side effects

Respiratory Care

Pulmonary Support:^[7][14]

• Monitoring: Regular assessment of respiratory function
• Airway management: Assistance with secretion clearance
• Ventilatory support: Non-invasive ventilation when indicated
• Aspiration prevention: Careful feeding management

Nutritional Support

Feeding Management:^[7][14]

• Nutritional assessment: Regular monitoring of growth and nutrition
• Feeding assistance: Modified textures, assisted feeding
• Gastrostomy: May be required for safe nutrition delivery
• Multidisciplinary team: Involvement of dietitians and speech therapists

Supportive Care

Physical Therapy

Mobility and Function:^[5]

• Range of motion: Prevention of contractures
• Positioning: Proper positioning to prevent deformities
• Adaptive equipment: Wheelchairs, supports, orthotics
• Family training: Education for home care providers

Ophthalmological Care

Vision Support:^[5]

• Regular monitoring: Assessment of eye problems and complications
• Low vision services: Maximizing remaining visual function
• Protective measures: Eye protection from injury
• Surgical intervention: For treatable conditions like cataracts

Family Support

Psychosocial Services:^[5]

• Genetic counseling: Family planning and inheritance information
• Support groups: Connection with other affected families
• Respite care: Temporary relief for primary caregivers
• Educational resources: Information about the condition and care

Prognosis and Natural History

Disease Course

Uniformly Poor Prognosis: HARD syndrome/Walker-Warburg syndrome has a uniformly lethal prognosis at an early age:^[14][7][5]

Survival Statistics:^[7][14]

• Most patients: Die before their second birthday
• Neonatal period: Some do not survive beyond the first few weeks
• Maximum survival: Rare cases may reach early childhood
• Causes of death: Respiratory complications, aspiration, infections

Factors Affecting Prognosis

Severity Indicators:^[14][5]

• Respiratory involvement: Early respiratory compromise indicates poor prognosis
• Feeding difficulties: Severe feeding problems increase complications
• Hydrocephalus severity: Massive hydrocephalus may limit survival
• Associated anomalies: Additional malformations worsen outlook

Quality of Life Considerations

Functional Limitations:^[7][5]

• Severe disability: Profound intellectual and physical disabilities
• No independent function: Complete dependence for all care
• Comfort care focus: Emphasis on comfort and family support
• Palliative approach: Often appropriate given poor prognosis

Genetic Counseling and Family Planning

Inheritance Pattern

Autosomal Recessive:^[7][5]

• Carrier parents: Both parents must be carriers (25% risk each pregnancy)
• Consanguinity: Increased risk in consanguineous marriages
• Population screening: May be appropriate in high-risk populations
• Genetic heterogeneity: Multiple genes can cause the same phenotype

Reproductive Counseling

Family Planning Options:^[7]

• Genetic counseling: Essential for all families
• Prenatal diagnosis: Available for families with known mutations
• Preimplantation genetic diagnosis: Option for affected families
• Adoption: Alternative family building option

Risk Assessment:

• Recurrence risk: 25% for each subsequent pregnancy
• Carrier testing: Available for family members
• Population screening: Appropriate in certain populations

Research and Future Directions

Current Research Areas

Pathophysiology Studies:^[10][21]

• Glycosylation pathways: Understanding α-dystroglycan modification
• Animal models: Mouse models for studying disease mechanisms
• Biomarker development: Identification of disease progression markers
• Natural history studies: Better characterization of disease course

Therapeutic Research:

• Gene therapy: Potential approaches for genetic correction
• Pharmacological interventions: Drugs targeting glycosylation pathways
• Stem cell therapy: Regenerative approaches for muscle and brain
• Symptomatic treatments: Improved supportive care strategies

Emerging Technologies

Diagnostic Advances:

• Next-generation sequencing: Comprehensive genetic testing panels
• Functional assays: Better assessment of protein function
• Prenatal testing: Improved early detection methods
• Biomarker discovery: Non-invasive monitoring tools

Therapeutic Development:

• Gene editing: CRISPR and other editing technologies
• Protein replacement: Enzyme replacement strategies
• Regenerative medicine: Tissue engineering approaches
• Precision medicine: Individualized treatment strategies

Global Health Perspectives

Healthcare Access and Challenges

Developed Countries:

• Specialized centers: Access to multidisciplinary teams
• Genetic services: Comprehensive testing and counseling
• Supportive care: Advanced life support and comfort care
• Research participation: Opportunities for clinical studies

Resource-Limited Settings:

• Diagnostic challenges: Limited access to genetic testing
• Basic supportive care: Focus on comfort and symptom management
• Family support: Community-based care approaches
• Prevention strategies: Genetic counseling and education

Public Health Implications

Population Screening:

• High-risk populations: Targeted screening in consanguineous communities
• Carrier detection: Identification of heterozygous carriers
• Prenatal care: Integration into routine obstetric care
• Education programs: Awareness among healthcare providers

Ethical Considerations

End-of-Life Care

Palliative Care Decisions:

• Comfort-focused care: Emphasis on quality of life over quantity
• Family-centered approach: Respecting family values and preferences
• Cultural considerations: Incorporating cultural and religious beliefs
• Advanced directives: Planning for end-of-life care

Prenatal Testing and Pregnancy Management

Reproductive Choices:

• Informed consent: Comprehensive counseling about testing options
• Pregnancy termination: Support for difficult decisions
• Continuing pregnancy: Support for families who choose to continue
• Non-directive counseling: Respecting autonomous decision-making

Conclusion

HARD syndrome, representing the original nomenclature for Walker-Warburg syndrome, stands as one of the most severe and devastating genetic conditions affecting human development. This autosomal recessive disorder exemplifies the critical importance of α-dystroglycan glycosylation in muscle, brain, and eye development, demonstrating how defects in a single molecular pathway can result in profound multi-system abnormalities.

The syndrome’s pathophysiology, rooted in defective O-mannosylation of α-dystroglycan due to mutations in POMT1, POMT2, and related genes, has provided crucial insights into the molecular mechanisms underlying congenital muscular dystrophies and neuronal migration disorders. The identification of these genetic causes has not only improved diagnostic capabilities but has also opened avenues for potential therapeutic interventions targeting the glycosylation pathway.

From a clinical perspective, the syndrome’s characteristic tetrad of hydrocephalus, agyria (cobblestone lissencephaly), retinal dysplasia, and often encephalocele creates a devastating constellation of abnormalities that severely impacts all aspects of development and function. The uniformly poor prognosis, with most affected children dying before their second birthday, underscores the severity of the condition and the challenges faced by families and healthcare providers.

The diagnostic approach to HARD syndrome has evolved significantly with advances in molecular genetics and neuroimaging. The availability of comprehensive genetic testing panels allows for definitive diagnosis and enables informed genetic counseling for families. Prenatal diagnosis through fetal imaging and genetic testing provides options for early detection, though it also presents difficult ethical and emotional challenges for families.

Current management remains entirely supportive and palliative, focusing on comfort care and prevention of complications. The treatment of hydrocephalus through ventriculoperitoneal shunting, management of respiratory complications, and provision of appropriate nutritional support can improve quality of life, though they do not alter the fundamental prognosis of the condition.

The genetic counseling implications of HARD syndrome are particularly significant given its autosomal recessive inheritance pattern and the 25% recurrence risk for subsequent pregnancies. The availability of prenatal diagnosis and preimplantation genetic diagnosis provides reproductive options for affected families, though these require careful ethical consideration and comprehensive counseling support.

Research directions in HARD syndrome hold promise for future therapeutic advances. Gene therapy approaches targeting the underlying enzymatic deficiencies, pharmacological interventions aimed at enhancing glycosylation pathways, and regenerative medicine strategies represent potential avenues for treatment development. However, the severity of the brain malformations and the early onset of symptoms present significant challenges for therapeutic intervention.

The study of HARD syndrome has also contributed significantly to our broader understanding of congenital muscular dystrophies and neuronal migration disorders. The identification of the dystroglycanopathy pathway has led to the recognition of an entire class of related disorders, improving diagnosis and classification of similar conditions.

Animal models of HARD syndrome, particularly mouse models with targeted mutations in POMT genes, continue to provide valuable insights into disease mechanisms and serve as platforms for therapeutic testing. These models have been instrumental in understanding the developmental consequences of α-dystroglycan hypoglycosylation and may facilitate the development of novel treatments.

The international collaboration required to study such rare conditions highlights the importance of global research networks and patient registries. The sharing of clinical data, genetic information, and research resources across institutions and countries is essential for advancing knowledge about HARD syndrome and developing new treatment approaches.

Healthcare providers should be aware of HARD syndrome as a consideration in newborns presenting with the characteristic combination of severe hypotonia, hydrocephalus, and eye abnormalities. Early recognition allows for appropriate supportive care, family counseling, and informed decision-making regarding treatment goals and end-of-life planning.

The syndrome also serves as an important model for studying the complex relationships between genetic mutations, protein function, and human development. The insights gained from understanding α-dystroglycan glycosylation have implications beyond HARD syndrome, potentially informing therapeutic approaches for other glycosylation disorders and neuromuscular conditions.

Looking toward the future, continued research investment in understanding the molecular mechanisms of HARD syndrome, developing therapeutic interventions, and improving supportive care will be essential for advancing the field. While a cure remains elusive, incremental advances in understanding and treatment may eventually improve outcomes for affected children and their families.

The story of HARD syndrome ultimately illustrates both the devastating impact of severe genetic disorders and the power of scientific research to illuminate disease mechanisms and provide hope for future treatments. As our understanding of glycobiology and neurodevelopment continues to evolve, the lessons learned from studying this rare but profound condition will undoubtedly contribute to broader advances in medical science and patient care.

References

1. https://medlineplus.gov/genetics/condition/walker-warburg-syndrome/  
2. https://en.wikipedia.org/wiki/Walker–Warburg_syndrome 
3. https://jamanetwork.com/journals/jamaneurology/fullarticle/579338 
4. https://rarediseases.org/rare-diseases/walker-warburg-syndrome/   
5. https://www.orpha.net/en/disease/detail/899                        
6. https://www.orphananesthesia.eu/en/rare-diseases/published-guidelines/walker-warburg-syndrome.html
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC1553431/                            
8. https://pubmed.ncbi.nlm.nih.gov/18513969/  
9. https://medlineplus.gov/genetics/gene/pomt2/   
10. https://pubmed.ncbi.nlm.nih.gov/20816175/  
11. https://medlineplus.gov/genetics/gene/pomt1/ 
12. https://www.cdghub.com/cdg/pomt1/ 
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC1048743/ 
14. https://www.medlink.com/articles/walker-warburg-syndrome           
15. https://www.orphananesthesia.eu/en/rare-diseases/published-guidelines/walker-warburg-syndrome/346-walker-warburg-syndrome/file.html 
16. https://thefetus.net/content/walker-warburg-syndrome-4 
17. https://www.orpha.net/en/disease/detail/588 
18. https://en.wikipedia.org/wiki/Muscle–eye–brain_disease
19. https://pubmed.ncbi.nlm.nih.gov/11320179/
20. http://www.morthoj.org/2011v5n1/Congenital_Muscular_Dystrophy.pdf
21. https://www.sciencedirect.com/science/article/pii/S0002929712005320
22. https://en.wikipedia.org/wiki/Hard_flaccid_syndrome
23. https://www.mayoclinic.org/diseases-conditions/rett-syndrome/symptoms-causes/syc-20377227
24. https://www.mayoclinic.org/diseases-conditions/ehlers-danlos-syndrome/diagnosis-treatment/drc-20362149
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC10606578/
26. https://my.clevelandclinic.org/health/diseases/rohhad-syndrome
27. https://pmc.ncbi.nlm.nih.gov/articles/PMC12185307/
28. https://auanews.net/issues/articles/2022/april-2022/hard-flaccid-syndrome-definition-diagnosis-and-management
29. https://www.chop.edu/conditions-diseases/goldenhar-syndrome
30. https://www.mayoclinic.org/diseases-conditions/guillain-barre-syndrome/diagnosis-treatment/drc-20363006
31. https://pubmed.ncbi.nlm.nih.gov/40624184/
32. https://my.clevelandclinic.org/health/diseases/22808-goldenhar-syndrome
33. https://my.clevelandclinic.org/health/diseases/6076-stiff-person-syndrome
34. https://www.nature.com/articles/s41443-025-01118-2
35. https://www.webmd.com/pain-management/chronic-pain-syndrome-overview
36. https://academic.oup.com/jsm/article/21/Supplement_6/qdae161.207/7917022
37. https://en.wikipedia.org/wiki/Ehlers–Danlos_syndrome
38. https://en.wikipedia.org/wiki/Genetic_disorder
39. https://www.neurology.org/doi/10.1212/WNL.56.8.1059
40. https://www.mayoclinic.org/diseases-conditions/prader-willi-syndrome/symptoms-causes/syc-20355997
41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2714190/
42. https://rarediseases.info.nih.gov/diseases/2598/parana-hard-skin-syndrome
43. https://pmc.ncbi.nlm.nih.gov/articles/PMC1040819/
44. https://my.clevelandclinic.org/health/diseases/24005-walker-warburg-syndrome
45. https://www.sciencedirect.com/topics/medicine-and-dentistry/walker-warburg-syndrome
46. https://rarediseases.info.nih.gov/diseases/156/muscle-eye-brain-disease
47. https://www.sciencedirect.com/science/article/abs/pii/S0960896609005690
48. https://rarediseases.org/mondo-disease/muscle-eye-brain-disease/